GlassScriptPhysician profile
Jason R Deleon
NPI 1497073787
$3,624.97
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $700 · 2021: $750 · 2022: $575 · 2023: $883 · 2024: $72.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.10 | 2019-2024 | Ubrelvy, Vraylar, Linzess |
| Lilly USA, LLC | $498.02 | 2019-2023 | Mounjaro |
| Pfizer INC. | $390.90 | 2019-2023 | |
| Allergan, INC. | $281.96 | 2019-2021 | |
| Gilead Sciences, INC. | $265.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $228.62 | 2019-2024 | Trelegy Ellipta |
| Genentech USA, INC. | $132.97 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $99.07 | 2019-2023 | Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $86.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $69.63 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.57 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.60 | 2022 | |
| Ironshore Pharmaceuticals INC. | $30.07 | 2019 | |
| Braeburn INC. | $17.30 | 2023 | Brixadi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16.62 | 2020 | |
| Amarin Pharma, INC. | $15.33 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.91 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.63 | 2022 | |
| Qiagen, LLC | $12.79 | 2021 | |
| Orexo US, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.